Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NCT05906576 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-05-22
Summary
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Conditions
- Crohn Disease
Interventions
- DRUG
-
Infliximab in the treatment of Crohn's disease in children
Sponsors & Collaborators
-
Taizhou Mabtech Pharmaceutical Co.,Ltd
lead INDUSTRY
Principal Investigators
-
Wu Jie · Beijing Children's Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-21
- Primary Completion
- 2026-11-30
- Completion
- 2027-02-28
Countries
- China
Study Locations
More Related Trials
-
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
NCT00325078 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Combined Immunosuppression for Pediatric Crohn's Disease
NCT05043870 ·Status: RECRUITING ·Phase: PHASE4
-
Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease
NCT05705856 ·Status: UNKNOWN
-
Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT00655733 ·Status: COMPLETED ·Phase: PHASE2
-
Fecal Microbiota Transplantation in Pediatric Crohn's Disease
NCT05321745 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease
NCT01559142 ·Status: UNKNOWN ·Phase: PHASE3
-
The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry
NCT00553176 ·Status: COMPLETED
-
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
NCT06673134 ·Status: ACTIVE_NOT_RECRUITING
-
PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease
NCT01759017 ·Status: TERMINATED
-
Precise Infliximab Exposure and Pharmacodynamic Control
NCT05660746 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease
NCT00206661 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)
NCT00705471 ·Status: TERMINATED
-
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
NCT01181765 ·Status: COMPLETED ·Phase: PHASE4
-
Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
NCT04530877 ·Status: WITHDRAWN ·Phase: PHASE4
-
Treatment With Infliximab in a Medical Setting (Study P05587)
NCT00752622 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031 ·Status: RECRUITING
-
A Multicentered Prospective Cohort Study of Chinese IBD Patients
NCT05386290 ·Status: UNKNOWN
-
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
NCT01580670 ·Status: COMPLETED ·Phase: PHASE3
-
A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab
NCT07263477 ·Status: COMPLETED
-
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
NCT05321758 ·Status: RECRUITING ·Phase: NA
-
Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography
NCT00819663 ·Status: COMPLETED
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT01277666 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
NCT00055367 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
NCT00269854 ·Status: COMPLETED ·Phase: PHASE2/PHASE3